Author:
Ural A. Ugur,Yilmaz M. Ilker,Avcu Ferit,Pekel Aysel,Zerman Murat,Nevruz Oral,Sengul Ali,Yalcin Atilla
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease.Drugs. 1991;42:919–944.
2. Berenson J, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.N Engl J Med. 1996;334:488–493.
3. McCloskey E, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma.Br J Haematol. 1998;100: 317–325.
4. Lövik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groat H, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors in to mature osteoclasts: the effect of a bisphosphonate.J Bone Miner Res. 1988;3:185–192.
5. Hughes DE, Mac Donald BR, Russel RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.J Clin Invest. 1989;83:1930–1935.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献